Format

Send to

Choose Destination
Leukemia. 2019 May 20. doi: 10.1038/s41375-019-0488-7. [Epub ahead of print]

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.

Author information

1
Department of Hematology, Beijing Boren Hospital, Beijing, 100070, China.
2
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological disorders, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
3
Cytology Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
4
Department of Bone Marrow Transplantation, Beijing Boren Hospital, Beijing, 100070, China.
5
Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
6
Medical Laboratory, Beijing Boren Hospital, Beijing, 100070, China.
7
Gaobo Healthcare Group, Beijing, China.
8
Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China. alexhchang@yahoo.com.
9
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological disorders, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China. fengxiaoming@ihcams.ac.cn.
10
Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, 350001, China. fengxiaoming@ihcams.ac.cn.
11
Department of Hematology, Beijing Boren Hospital, Beijing, 100070, China. tongcr@borenhospital.com.

Abstract

Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell therapy in 34 relapsed or refractory (r/r) B-ALL pediatric and adult patients who failed from previous CD19 CAR T-cell therapy. Complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 24 of 30 patients (80%) that could be evaluated on day 30 after infusion, which accounted for 70.5% of all 34 enrolled patients. Most patients only experienced mild cytokine-release syndrome and neurotoxicity. Seven CR patients received no further treatment, and 3 of them remained in remission at 6, 6.6, and 14 months after infusion. Eleven CR patients were promptly bridged to transplantation, and 8 of them remained in remission at 4.6 to 13.3 months after transplantation, resulted in 1-year leukemia-free survival rate of 71.6% (95% CI, 44.2-99.0). CD22 antigen loss or mutation was not observed to be associated with relapsed patients. Our study demonstrated that our CD22 CAR T-cells was highly effective in inducing remission in r/r B-ALL patients, and also provided a precious window for subsequent transplantation to achieve durable remission.

PMID:
31110217
DOI:
10.1038/s41375-019-0488-7

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center